Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA Recommends Approval For Astellas’ Mycamine

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that Astellas Pharma's antifungal Mycamine (micafungin) be approved for candidiasis, Astellas announced Feb. 21
Advertisement

Related Content

Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
Astellas Wins Additional U.S. Indications For Antifungal Mycamine
Advertisement
UsernamePublicRestriction

Register

SC067722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel